ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

KRRO Korro Bio Inc

41.60
-0.90 (-2.12%)
Jun 15 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 48,524
Bid Price 37.98
Ask Price 119.87
News -
Day High 44.2983

Low
13.00

52 Week Range

High
97.91

Day Low 41.16
Company Name Stock Ticker Symbol Market Type
Korro Bio Inc KRRO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.90 -2.12% 41.60 00:00:15
Open Price Low Price High Price Close Price Prev Close
42.43 41.16 44.2983 41.60 42.50
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,486 48,524 $ 42.91 $ 2,082,026 - 13.00 - 97.91
Last Trade Time Type Quantity Stock Price Currency
16:00:05 formt 272 $ 41.60 USD

Korro Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
30.4M 738.53k - 0 -81.17M -109.91 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Korro Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No KRRO Message Board. Create One! See More Posts on KRRO Message Board See More Message Board Posts

Historical KRRO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week43.113848.79541.1644.3149,714-1.51-3.51%
1 Month51.1755.9941.1648.5545,761-9.57-18.70%
3 Months67.8497.9141.1661.7840,832-26.24-38.68%
6 Months50.6797.9138.746558.0534,073-9.07-17.90%
1 Year13.0097.9113.0053.0143,47828.60220.00%
3 Years13.0097.9113.0053.0143,47828.60220.00%
5 Years13.0097.9113.0053.0143,47828.60220.00%

Korro Bio Description

Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss.